| Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase I | Treatment | Approved-not yet active | 18 and over | CA184-033
NCT00732186 |
Trial Description
Summary The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML Eligibility Criteria Inclusion Criteria: - Ph+ CML on dasatinib therapy
- Loss of cytogenetic or molecular response while on dasatinib therapy
- On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment
Exclusion Criteria: - Uncontrolled or significant cardiovascular disease
Trial Contact Information
Trial Lead Organizations/Sponsors Bristol-Myers Squibb Company - New York | Bristol-Myers Squibb |  | Study Director |
| For participation information at a USA site use a phone number below. For site information outside the USA please email: | | | | |
Email:
Clinical.Trials@bms.com |
| First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time. | | |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00732186
Information obtained from ClinicalTrials.gov on April 23, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
